Barclays Reiterates “€33.00” Price Target for Fresenius SE & Co. KGaA (FRA:FRE)

Barclays set a €33.00 ($33.67) target price on Fresenius SE & Co. KGaA (FRA:FREGet Rating) in a research note issued to investors on Tuesday morning, Borsen Zeitung reports.

FRE has been the subject of several other research reports. Deutsche Bank Aktiengesellschaft set a €25.00 ($25.51) target price on shares of Fresenius SE & Co. KGaA in a research note on Tuesday, November 1st. UBS Group set a €30.00 ($30.61) target price on shares of Fresenius SE & Co. KGaA in a research note on Monday, October 31st. Morgan Stanley set a €28.00 ($28.57) target price on shares of Fresenius SE & Co. KGaA in a research note on Tuesday, October 18th. set a €36.00 ($36.73) price objective on shares of Fresenius SE & Co. KGaA in a research note on Friday, July 29th. Finally, Credit Suisse Group set a €24.00 ($24.49) price objective on shares of Fresenius SE & Co. KGaA in a research note on Wednesday, November 9th.

Fresenius SE & Co. KGaA Trading Up 0.6 %

FRE opened at €25.37 ($25.89) on Tuesday. The firm has a 50-day moving average price of €22.64 and a 200-day moving average price of €26.20. Fresenius SE & Co. KGaA has a twelve month low of €60.16 ($61.39) and a twelve month high of €80.00 ($81.63).

About Fresenius SE & Co. KGaA

(Get Rating)

Fresenius SE & Co KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.

Read More

Receive News & Ratings for Fresenius SE & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.